Quality of life and costs for different treatment strategies for rheumatoid arthritis

References

• Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J. Rheumatol. 26, 717–719 (1999).
   PubMed Web of Science ®Google Scholar
• Pincus T. Long-term outcomes in rheumatoid arthritis. Br. J. Rheumatol. 34, 59–73 (1995).
   PubMedGoogle Scholar
• Plant MJ, Jones PW, Saklatvala J, Ollier WER, Dawes PT. Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J. Rheumatol. 25, 417–426 (1998).
   PubMed Web of Science ®Google Scholar
• Harle P, Bongartz T, Scholmerich J, Muller-Ladner U, Straub RH. Predictive and potentially predictive factors in early arthritis: a multidisciplinary approach. J. Rheumatol. 44(4), 426–433 (2005).
   Google Scholar
• Aho K, Heliovaara M. Risk factors for rheumatoid arthritis. Ann. Med. 36, 242–251 (2004).
   PubMed Web of Science ®Google Scholar
• Wiles N, Symmons DPM, Harrison B et al. Estimating the incidence of rheumatoid arthritis – trying to hit a moving target? Arthritis Rheum. 42, 1339–1346 (1999).
   PubMed Web of Science ®Google Scholar
• Macgregor AJ, Silman AJ. Classification and epidemiology. In: Rheumatology. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Eds). Mosby, Toronto, Canada (2003).
   Google Scholar
• Doran MF, Pond GR, Crowson CS, O’Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 46, 625–631 (2002).
   PubMed Web of Science ®Google Scholar
• Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br. J. Rheumatol. 33, 735–739 (1994).
   PubMedGoogle Scholar
• Heiberg T, Finset A, Kvien TK. Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64, 191–195 (2005).
   PubMed Web of Science ®Google Scholar
• Krishnan E, Fries JF. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am. J. Med. 115, 371–376 (2003).
   PubMed Web of Science ®Google Scholar
• Welsing PMJ, Fransen J, Van Riel PLCM. Is the disease course becoming of rheumatoid arthritis becoming milder? Time trends in an inception cohort of early rheumatoid arthritis since 1985. (Arthritis Rheum. Submitted A&R) (2005) (In Press).
   Google Scholar
• Gabriel SE, Crowson CS, Kremers HM et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum.48, 54–58 (2003).
   PubMed Web of Science ®Google Scholar
• Boers M, Dijkmans B, Gabriel S, Maradit-Kremers H, O’Dell J, Pincus T. Making an impact on mortality in rheumatoid arthritis. Arthritis Rheum.50, 1734–1739 (2004).
   PubMed Web of Science ®Google Scholar
• Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: Evolving concepts. Arthritis Rheum. 44, 1234–1236 (2001).
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA et al. The American-Rheumatism-Association 1987 Revised Criteria for the Classification of Rheumatoid-Arthritis. Arthritis Rheum. 31, 315–324 (1988).
   PubMed Web of Science ®Google Scholar
• Macgregor AJ. Classification criteria for rheumatoid arthritis. Baillieres Clin. Rheumatol. 9, 287–304 (1995).
   PubMed Web of Science ®Google Scholar
• Kwoh CK, Anderson LG, Greene JM et al. Guidelines for the management of rheumatoid arthritis–2002 update. Arthritis Rheum. 46, 328–346 (2002).
   PubMedGoogle Scholar
• Gremillion RB, Van Vollenhoven RF. Rheumatoid arthritis. Designing and implementing a treatment plan. Postgrad. Med. 103, 103–108 (1998).
   PubMed Web of Science ®Google Scholar
• Cohen S, Cannon GW, Schiff M et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum. 44, 1984–1992 (2001).
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130, 478–486 (1999).
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. Lancet 354, 1932–1939 (1999).
   PubMed Web of Science ®Google Scholar
• Cohen SB, Moreland LW, Cush JJ et al. A multicentre, double-blind, randomised, placebo-controlled trial of anakinra (Kineret), a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63, 1062–1068 (2004).
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M et al. The American College Of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 36, 729–740 (1993).
   PubMed Web of Science ®Google Scholar
• Boers M, Tugwell P, Felson DT et al. World Health Organization and International League of Associations for Rheumatology core end points for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J. Rheumatol. 21, 86–89 (1994).
   Google Scholar
• Van der Heijde DMFM, Van ‘t Hof M, Van Riel PLCM, Van de Putte LBA. Validity of single variables and indexes to measure disease activity in rheumatoid arthritis. J. Rheumatol. 20, 538–541 (1993).
   PubMed Web of Science ®Google Scholar
• Prevoo MLL, Van ‘t Hof MA, Kuper HH, Van Leeuwen MA, Van de Putte LBA, Van Riel PLCM. Modified disease activity scores that include 28 joint counts – development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38, 44–48 (1995).
   PubMed Web of Science ®Google Scholar
• Van der Heijde DMFM, Van ‘t Hof MA, Van Riel PLCM, Van de Putte L. Disease activity score. Ann. Rheum. Dis.51,140 (1992).
   PubMedGoogle Scholar
• Salaffi F, Stancati A, Carotti M. Responsiveness of health status measures and utility-based methods in patients with rheumatoid arthritis. Clin. Rheumatol. 21, 478–487 (2002).
   PubMed Web of Science ®Google Scholar
• Van der Heijde DMFM, Van ‘t Hof MA, Van Riel PLCM et al. Judging disease activity in clinical practice in rheumatoid arthritis – 1st step in the development of a disease activity score. Ann. Rheum. Dis.49,916–920 (1990).
   PubMed Web of Science ®Google Scholar
• Van Gestel AM, Prevoo MLL, Van ‘t Hof MA, Van Rijswijk MH, Van de Putte LBA, Van Riel PLCM. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis – comparison with the preliminary American College of Rheumatology and the World Health Organization International League Against Rheumatism criteria. Arthritis Rheum. 39, 34–40 (1996).
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology – preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727–735 (1995).
   PubMed Web of Science ®Google Scholar
• Van Gestel AM, Prevoo MLL, Van ‘t Hof MA, Van Rijswijk MH, Van de Putte LBA, Van Riel PLCM. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis – comparison with the preliminary American College of Rheumatology and the World Health Organization International League Against Rheumatism criteria. Arthritis Rheum. 39, 34–40 (1996).
   PubMed Web of Science ®Google Scholar
• Van der Heijde DMFM. Plain x-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. Baillieres Clin. Rheumatol. 10, 435–453 (1996).
   PubMed Web of Science ®Google Scholar
• Pincus T, Larsen A, Brooks RH, Kaye J, Nance EP, Callahan LF. Comparison of 3 quantitative measures of hand radiographs in patients with rheumatoid arthritis: Steinbrocker stage, Kaye modified Sharp score, and Larsen score. J. Rheumatol. 24, 2106–2112 (1997).
   PubMedGoogle Scholar
• Fries JF, Spitz PW, Young DY. The dimensions of health outcomes – the health assessment questionnaire, disability and pain scales. J. Rheumatol. 9, 789–793 (1982).
   PubMed Web of Science ®Google Scholar
• Russell AS, Conner-Spady B, Mintz A, Mallon C, Maksymowych WP. The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. J. Rheumatol. 30, 941–947 (2003).
   PubMed Web of Science ®Google Scholar
• Marra CA, Woolcott JC, Kopec JA et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc. Sci. Med. 60, 1571–1582 (2005).
   PubMed Web of Science ®Google Scholar
• Luo N, Chew LH, Fong KY et al. A comparison of the EuroQol-5D and the Health Utilities Index mark 3 in patients with rheumatic disease. J. Rheumatol. 30, 2268–2274 (2003).
   PubMed Web of Science ®Google Scholar
• Marra CA, Marion SA, Guh D et al. All QALYs are not equal: lessons learned in an economic evaluation of rheumatoid arthritis. Ann. Rheum. Dis. 63, 77 (2004).
   Google Scholar
• Meenan RF, Gertman PM, Mason JH. Measuring health-status in arthritis – arthritis impact measurement scales. Arthritis Rheum. 23, 146–152 (1980).
   PubMed Web of Science ®Google Scholar
• De Jong Z, Van der Heijde D, Mc Kenna SP, Whalley D. The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument. Br. J. Rheumatol. 36, 878–883 (1997).
   PubMedGoogle Scholar
• Ware JE, Sherbourne CD. The Mos 36-Item Short-Form Health Survey (Sf-36).1. Conceptual-framework and item selection. Med. Care 30, 473–483 (1992).
   PubMed Web of Science ®Google Scholar
• Hunt SM, Mc Ewen J, Mc Kenna SP. Measuring health-status – a new tool for clinicians and epidemiologists. J. R. Coll. Gen. Pract. 35, 185–188 (1985).
   Google Scholar
• Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann. Med. 33, 375–384 (2001).
   PubMed Web of Science ®Google Scholar
• EuroQol group. EuroQol–a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16, 199–208 (1990).
   PubMed Web of Science ®Google Scholar
• Lubeck DP. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 22, 27–38 (2004).
   PubMed Web of Science ®Google Scholar
• Meenan RF, Mason JH, Anderson JJ, Guccione AA, Kazis LE. Aims2 – the content and properties of a revised and expanded arthritis impact measurement scales health-status questionnaire. Arthritis Rheum. 35, 1–10 (1992).
   PubMed Web of Science ®Google Scholar
• Wells G, Boers M, Shea B et al. Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis: preliminary findings in the generic health OMERACT study. J. Rheumatol. 26, 217–221 (1999).
   PubMed Web of Science ®Google Scholar
• Talamo J, Frater A, Gallivan S, Young A. Use of the short form 36 (SF36) for health status measurement in rheumatoid arthritis. Br. J. Rheumatol. 36, 463–469 (1997).
   PubMedGoogle Scholar
• Ruta DA, Hurst NP, Kind P, Hunter M, Stubbings A. Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36). Br. J. Rheumatol. 37, 425–436 (1998).
   PubMedGoogle Scholar
• Essink-Bot ML, Krabbe PF, Bonsel GJ, Aaronson NK. An empirical comparison of four generic health status measures. The Nottingham Health Profile, the Medical Outcomes Study 36-item Short-Form Health Survey, the COOP/WONCA charts, and the EuroQol instrument. Med. Care 35, 522–537 (1997).
   PubMed Web of Science ®Google Scholar
• Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br. J. Rheumatol. 36, 551–559 (1997).
   PubMedGoogle Scholar
• Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br. J. Rheumatol. 36, 786–793 (1997).
   PubMedGoogle Scholar
• Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI(R)): concepts, measurement properties and applications. Health Qual. Life Outcomes. 1, 54 (2003).
   PubMedGoogle Scholar
• Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 21, 271–92 (2002).
   Google Scholar
• Fautrel B, Guillemin F. Cost of illness studies in rheumatic diseases. Curr. Opin. Rheumatol. 14, 121–126 (2002).
   PubMed Web of Science ®Google Scholar
• Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 39, 28–33 (2000).
   PubMed Web of Science ®Google Scholar
• Lajas C, Abasolo L, Bellajdel B et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 49, 64–70 (2003).
   PubMedGoogle Scholar
• van Jaarsveld CHM, Jacobs JWG, Schrijvers AJP, Heurkens AHM, Haanen HCM, Bijlsma JWJ. Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Br. J. Rheumatol. 37, 837–847 (1998).
   PubMedGoogle Scholar
• Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis – the impact of poor function and functional decline. Arthritis Rheum. 42, 1209–1218 (1999).
   PubMed Web of Science ®Google Scholar
• Verstappen SMM, Jacobs JWG, Bijlsma JWJ. The Utrecht experience with different treatment strategies in early rheumatoid arthritis. Clin. Exp. Rheumatol. 21, S165–S168 (2003).
   Google Scholar
• Clarke AE, Levinton C, Joseph L et al. Predicting the short-term direct medical costs incurred by patients with rheumatoid arthritis. J. Rheumatol. 26, 1068–1075 (1999).
   PubMedGoogle Scholar
• Rat AC, Boissier MC. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 71, 518–524 (2004).
   PubMed Web of Science ®Google Scholar
• Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis – composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum. 44, 528–534 (2001).
   PubMed Web of Science ®Google Scholar
• Ruof J, Merkesdal S, Huelsemann JL et al. Cost assessment instruments in Rheumatology: evaluation of applied instrument characteristics. J. Rheumatol. 28, 662–665 (2001).
   PubMedGoogle Scholar
• Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130, 478–486 (1999).
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Drummond M, Maetzel A et al. OMERACT 6 Economics Working group Report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J. Rheumatol. 30(4), 886–890 (2003).
   PubMed Web of Science ®Google Scholar
• Buxton MJ, Drummond MF, Van Hout BA et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 6, 217–227 (1997).
   PubMed Web of Science ®Google Scholar
• Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis 5. Working with Markov processes. Med. Decis. Making 17, 152–159 (1997).
   PubMed Web of Science ®Google Scholar
• Verburg RJ, Sont JK, Vlieland TPMV et al. High dose chemotherapy followed by autologous peripheral blood stem cell transplantation or conventional pharmacological treatment for refractory rheumatoid arthritis? A Markov decision analysis. J. Rheumatol. 28, 719–727 (2001).
   PubMedGoogle Scholar
• Albert DA, Aksentijevich S, Hurst S, Fries JF, Wolfe F. Modeling therapeutic strategies in rheumatoid arthritis: use of decision analysis and Markov models. J. Rheumatol. 27, 644–652 (2000).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 42, 347–356 (1999).
   PubMed Web of Science ®Google Scholar
• Fletcher M, Brennan RW, Norrie DH. Modeling and reconfiguring intelligent holonic manufacturing systems with internet-based mobile agents. J. Intelligent Manufact.14, 7–23 (2003).
   Web of Science ®Google Scholar
• Wong JB, Kavanagh A. Estimating the cost–effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am. J. Med. 113, 400–408 (2002).
   PubMed Web of Science ®Google Scholar
• Lajas C, Abasolo L, Bellajdel B et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum.49,64–70 (2003).
   PubMed Web of Science ®Google Scholar
• Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis – introduction. Health Technol. Assess. 8(11), 1–91 (2004).
   Google Scholar
• Clark W, Jobanputra P, Barton P, Burls A. The clinical and cost–effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol. Assess. 8 (18), 1–105 (2004).
   Web of Science ®Google Scholar
• Lajas C, Abasolo L, Bellajdel B et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 49, 64–70 (2003).
   PubMed Web of Science ®Google Scholar
• Welsing PMJ, Severens JL, Hartman M, Van Riel PLCM, Laan RFJM. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in The Netherlands. Arthritis Rheum. 964–973 (2004).
   PubMedGoogle Scholar
• Drummond MF, O’Brien BJ, Stoddard GL, Torrance G. Methods for the Economic Evaluation of Healthcare Programmess. Oxford Medical Publications, Oxford, UK (1997).
   Google Scholar
• Maetzel A, Tugwell P, Boers M et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J. Rheumatol. 30, 891–896 (2003).
   PubMedGoogle Scholar
• Lajas C, Abasolo L, Bellajdel B et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 49, 64–70 (2003).
   PubMed Web of Science ®Google Scholar
• Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JMW. Long-term course and outcome of functional capacity in rheumatoid arthritis – the effect of disease activity and radiologic damage over time. Arthritis Rheum. 42, 1854–1860 (1999).
   PubMed Web of Science ®Google Scholar
• Welsing PMJ, van Gestel AM, Swinkels HL, Kiemeney LALM, Van Riel PLCM. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 44, 2009–2017 (2001).
   PubMed Web of Science ®Google Scholar
• Zandbelt MM, Welsing PMJ, van Gestel AM, Van Riel PLCM. Health assessment questionnaire modifications: is standardisation needed? Ann. Rheum. Dis. 60, 841–845 (2001).
   PubMed Web of Science ®Google Scholar
• Welsing PMJ, Landewe RBM, Van Riel PLCM et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis – a longitudinal analysis. Arthritis Rheum. 50, 2082–2093 (2004).
   PubMed Web of Science ®Google Scholar
• Weinstein MC, O’Brien B, Hornberger J et al. Principles of good practice for decision analytic modeling in healthcare evaluation: report of the ISPOR task force on good research practices-modeling studies. Value Health 6, 9–17 (2003).
   PubMed Web of Science ®Google Scholar
• Welsing PMJ, Severens JL, Laan RFJM. Optimistic assumptions in modelling studies have a substantial influence on the cost–effectiveness result. Rheumatology 42, 1574–1575 (2003).
   PubMedGoogle Scholar
• Eberhardt KB, Truedsson L, Pettersson H et al. Disease activity and joint damage progression in early rheumatoid arthritis – relation to Igg, Iga, and Igm rheumatoid factor. Ann. Rheum. Dis. 49, 906–909 (1990).
   PubMed Web of Science ®Google Scholar
• Fries JF. Current treatment paradigms in rheumatoid arthritis. Rheumatology 39, 30–35 (2000).
   PubMedGoogle Scholar
• Kremers HM, Nicola P, Crowson CS, O’Fallon WM, Gabriel SE. Therapeutic strategies in rheumatoid arthritis over a 40-year period. J. Rheumatol. 31(12), 2366–2376 (2004).
   PubMedGoogle Scholar
• Pincus T, Yazici Y, Sokka I, Aletaha D, Smolen JS. Methotrexate as the ‘anchor drug’ for the treatment of early rheumatoid arthritis. Clin. Exp. Rheumatol. 21, S179–S185 (2003).
   Google Scholar
• Maddison P, Kiely P, Kirkham B et al. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology 44, 280–286 (2005).
   PubMed Web of Science ®Google Scholar
• Vingerhoets AJ, Bekker MH, Laan AJ. Sex differences in emotional expressivity and mental health: is the expression of emotions healthy? Psychosom. Med. 63, 146 (2001).
   Google Scholar
• Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263–269 (2004).
   PubMed Web of Science ®Google Scholar
• Fransen J, Stucki G, Twisk J et al. Effectiveness of a measurement feedback system on outcome in rheumatoid arthritis: a controlled clinical trial. Ann. Rheum. Dis. 62, 624–629 (2003).
   PubMed Web of Science ®Google Scholar
• Mottonen T, Hannonen P, Korpela M et al. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum. 46, 894–898 (2002).
   PubMed Web of Science ®Google Scholar
• Albers JMC, Paimela L, Kurki P et al. Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann. Rheum. Dis. 60, 453–458 (2001).
   PubMed Web of Science ®Google Scholar
• Landewe RBM, Boers M, Verhoeven AC et al. COBRA combination therapy in patients with early rheumatoid arthritis – long-term structural benefits of a brief intervention. Arthritis Rheum. 46, 347–356 (2002).
   PubMed Web of Science ®Google Scholar
• van Jaarsveld CHM, Jacobs JWG, van der Veen MJ et al. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. Ann. Rheum. Dis. 59, 468–477 (2000).
   PubMedGoogle Scholar
• Puolakka K, Kautiainen H, Mottonen T et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis – a five-year randomized follow-up trial. Arthritis Rheum. 50, 55–62 (2004).
   PubMed Web of Science ®Google Scholar
• van Aken J, Lard LR, le Cessie S, Hazes JM, Breedveld FC, Huizinga TW. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann. Rheum. Dis. 63, 274–279 (2004).
   PubMed Web of Science ®Google Scholar
• Ward MM. Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980–1995: results from the national ambulatory medical care surveys. J. Rheumatol. 26, 546–550 (1999).
   Google Scholar
• Irvine S, Munro R, Porter D. Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice. Ann. Rheum. Dis. 58, 510–513 (1999).
   PubMedGoogle Scholar
• Goekoop YPM, Allaart CFR, Breedveld FC, Dijkmans BAC. Combination therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 13, 177–183 (2001).
   PubMedGoogle Scholar
• Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br. J. Rheumatol. 37, 612–619 (1998).
   PubMedGoogle Scholar
• Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch. Intern. Med. 159, 2542–2550 (1999).
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353, 259–266 (1999).
   PubMed Web of Science ®Google Scholar
• Kalden JR, Scott DL, Smolen JS. Improved functional ability in patients with rheumatoid arthritis – longterm treatment with leflunomide versus sulfasalazine. J. Rheumatol. 28(9), 1983–1991 (2001). Erratum in: J. Rheumatol. 29(1), 205 (2002).
   PubMedGoogle Scholar
• Strand V, Tugwell P, Bombardier C et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 42, 1870–1878 (1999).
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genovese MC, Cannon GW et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 137, 726–733 (2002).
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130, 478–486 (1999).
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 50, 1051–1065 (2004).
   PubMed Web of Science ®Google Scholar
• Torrance GW, Tugwell P, Amorosi S, Chartash E, Sengupta N. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human antiTNF monoclonal antibody) plus methotrexate. Rheumatology (Oxford) 43, 712–718 (2004).
   PubMed Web of Science ®Google Scholar
• Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S. Cost–effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. Br. J. Rheumatol. 37, 1102–1109 (1998).
   PubMedGoogle Scholar
• Korthals-de Bos IBC, van Tulder MW, Boers M et al. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone. J. Rheumatol. 31, 1709–1716 (2004).
   PubMed Web of Science ®Google Scholar
• Choi HK, Seeger JD, Kuntz KM. A cost–effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum. 43, 2316–2327 (2000).
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost–effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 43, 62–72 (2004).
   PubMed Web of Science ®Google Scholar
• Yazdani C, McLaughlin T, Cummins G, Doyle J. Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept. Am. J. Manag. Care7,S419–S426 (2001).
   Google Scholar
• Ollendorf DA, Peterson AN, Doyle J, Huse DM. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population. Am. J. Manag. Care8,S203–S213 (2002).
   Google Scholar
• Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Am. J. Manag. Care. 47, 655–661 (2002).
   Google Scholar
• Rutten-van Molken M, Buscbach van J, Rutten F. Van kosten tot effecten: een handleiding voor evaluatiestudies in de gezondheidszorg. Maarssen. Elsevier gezondheidszorg 31–41 (2000).
   Google Scholar
• George B, Harris A, Mitchell A. Cost effectiveness analysis and the consistency of decision making – evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 19, 1103–1109 (2001).
   PubMed Web of Science ®Google Scholar
• Taylor D. Funding medicines for people with multiple sclerosis. Br. Med. J. 323, 1379–1380 (2001).
   PubMed Web of Science ®Google Scholar
• Devlin N, Parkin D. Does NICE have a cost–effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 13, 437–452 (2004).
   PubMed Web of Science ®Google Scholar
• Jobanputra P, Wilson J, Douglas K, Burls A. A survey of British rheumatologists’ DMARD preferences for rheumatoid arthritis. Rheumatology 43, 206–210 (2004).
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR. Patient preferences for treatment of rheumatoid arthritis. Ann. Rheum. Dis.63,1372–1378 (2004).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Am. J. Manag. Care. 46, 1443–1450 (2002).
   Google Scholar
• Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human antitumor necrosis factor-α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Am. J. Manag. Care 48, 35–45 (2003).
   Google Scholar
• Furst DE, Schiff MH, Fleischmann RM et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 30, 2563–2571 (2003).
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Am. J. Manag. Care. 50, 1400–1411 (2004).
   Google Scholar
• van de Putte LB, Rau R, Breedveld FC et al. Efficacy and safety of the fully human antitumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, Phase II study. Ann. Rheum. Dis. 62, 1168–1177 (2003).
   PubMed Web of Science ®Google Scholar
• Van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63, 508–516 (2004).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340, 253–259 (1999).
   PubMed Web of Science ®Google Scholar
• Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M Jr. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. J. Formos. Med. Assoc. 103, 618–623 (2004).
   PubMedGoogle Scholar
• Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141–147 (1997).
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130, 478–486 (1999).
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343, 1586–1593 (2000).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Am. J. Manag. Care. 46, 1443–1450 (2002).
   Google Scholar
• St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Am. J. Manag. Care. 50, 3432–3443 (2004).
   Google Scholar
• Kremer JM, Genovese MC, Cannon GW et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 137,726–733 (2002).
   PubMed Web of Science ®Google Scholar
• Picavet HSJ, Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Ann. Rheum. Dis.63,723–729 (2004).
   PubMed Web of Science ®Google Scholar
• Verstappen SMM, Verkleij H, Bijlsma JWJ et al. Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann. Rheum. Dis.63,817–824 (2004).
   PubMed Web of Science ®Google Scholar